nivolumab,visugromab
catal ym,bms
['nivolumab', 'nivo', 'catalym']
catalym announces initial data from ongoing phase 2a trial evaluating gdf-15-targeting antibody visugromab in combination with nivolumab at asco 2023 
Breaking news from Business Wire